Comparative vascular responses three months after paclitaxel and everolimus-eluting stent implantation in streptozotocin-induced diabetic porcine coronary arteries

Cardiovascular Diabetology

Volumn 11, Issue , 2012, Pages

  Sheehy, Alexander ^a   Hsu, Steven ^a   Bouchard, Amelie ^b   Lema, Pablo ^b   Savard, Claudine ^b   Guy, Louis Georges ^b   Tai, Julie ^a   Polyakov, Igor ^a  

^a ABBOTT VASCULAR   (United States)

^b SOLVO BIOTECHNOLOGY   (Hungary)

Author keywords

Animal model; Everolimus eluting stent; Paclitaxel eluting stent; Percutaneous coronary intervention; Restenosis; Vascular response

Indexed keywords

CASPASE 3; EVEROLIMUS; FIBRIN; PACLITAXEL; TAXUS LIBERTE; UNCLASSIFIED DRUG;

ANGIOGRAPHY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BLOOD VESSEL REACTIVITY; CELL DEATH; CELL VIABILITY; CONTROLLED STUDY; CORONARY ARTERY; DRUG ELUTING STENT; ENDOTHELIUM CELL; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPERIMENTAL PIG; HISTOPATHOLOGY; HYPERGLYCEMIA; INFLAMMATION; MORPHOMETRICS; NEOINTIMA; NONHUMAN; PANCREAS ISLET BETA CELL; SMOOTH MUSCLE FIBER; STENOSIS; STREPTOZOCIN DIABETES;

ANIMALS; APOPTOSIS; CARDIOVASCULAR AGENTS; CELLS, CULTURED; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; CORONARY RESTENOSIS; CORONARY VESSELS; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; DIABETIC ANGIOPATHIES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG-ELUTING STENTS; ENDOTHELIAL CELLS; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; NECROSIS; NEOINTIMA; PACLITAXEL; PERCUTANEOUS CORONARY INTERVENTION; PROSTHESIS DESIGN; SIROLIMUS; SWINE; TIME FACTORS; WOUND HEALING;

EID: 84862503602     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-11-75     Document Type: Article

References (47)

1. Berry C, Tardif JC, Bourassa MG. Coronary heart disease in patients with diabetes: part I: recent advances in prevention and noninvasive management. J Am Coll Cardiol 2007, 49(6):631-642. 10.1016/j.jacc.2006.09.046, 17291928.
2. Boccara F, Cohen A. Interplay of diabetes and coronary heart disease on cardiovascular mortality. Heart 2004, 90(12):1371-1373. 10.1136/hrt.2004.035766, 1768583, 15547003.
3. Takara A, Ogawa H, Endoh Y, Mori F, Yamaguchi J, Takagi A, Koyanagi R, Shiga T, Kasanuki H, Hagiwara N. Long-term prognosis of diabetic patients with acute myocardial infarction in the era of acute revascularization. Cardiovasc Diabetol 2010, 9:1-7. 10.1186/1475-2840-9-1, 2815698, 20047694.
4. Xiao L, Huang DS, Tong JJ, Shen J. Efficacy of endoluminal interventional therapy in diabetic peripheral arterial occlusive disease: a retrospective trial. Cardiovasc Diabetol 2012, 11:17-27. 3305574, 22373102.
5. Hamamdzic D, Fenning RS, Patel D, Mohler ER, Orlova KA, Wright AC, Llano R, Keane MG, Shannon RP, Birnbaum MJ, Wilensky RL. Akt pathway is hypoactivated by synergistic actions of diabetes mellitus and hypercholesterolemia resulting in advanced coronary artery disease. Am J Physiol Heart Circ Physiol 2010, 299(3):H699-H706. 10.1152/ajpheart.00071.2010, 2944488, 20601459.
6. Carter AJ, Bailey L, Devries J, Hubbard B. The effects of uncontrolled hyperglycemia on thrombosis and formation of neointima after coronary stent placement in a novel diabetic porcine model of restenosis. Coron Artery Dis 2000, 11(6):473-479. 10.1097/00019501-200009000-00005, 10966133.
7. Zhang Q, Lu L, Pu L, Zhang R, Shen J, Zhu Z, Hu J, Yang Z, Chen Q, Shen W. Neointimal hyperplasia persists at six months after sirolimus-eluting stent implantation in diabetic porcine. Cardiovasc Diabetol 2007, 6:16-22. 10.1186/1475-2840-6-16, 1892541, 17550588.
8. Dolgov VV, Zaikina OE, Bondarenko MF, Repin VS. Aortic endothelium of alloxan diabetic rabbits: a quantitative study using scanning electron microscopy. Diabetologia 1982, 22(5):338-343.
9. Velander P, Theopold C, Hirsch T, Bleiziffer O, Zuhaili B, Fossum M, Hoeller D, Gheerardyn R, Chen M, Visovatti S, Svensson H, Yao F, Eriksson E. Impaired wound healing in an acute diabetic pig model and the effects of local hyperglycemia. Wound Repair Regen 2008, 16(2):288-293. 10.1111/j.1524-475X.2008.00367.x, 18318812.
10. Dickinson S, Rogers T, Kasiske B, Bertog S, Tadros G, Malik J, Wilson R, Panetta C. Coronary artery disease in young women and men with long-standing insulin-dependent diabetes. Angiology 2008, 59(1):9-15. 10.1177/0003319707304579, 18319217.
11. Jonas M, Edelman ER, Groothuis A, Baker AB, Seifert P, Rogers C. Vascular neointimal formation and signaling pathway activation in response to stent injury in insulin-resistant and diabetic animals. Circ Res 2005, 97(7):725-733. 10.1161/01.RES.0000183730.52908.C6, 16123336.
12. Kwon JS, Kim YS, Cho AS, Kim JS, Jeong SY, Hong MH, Jeong MH, Ahn Y. Origin of restenosis after drug-eluting stent implantation in hyperglycemia is inflammatory cells and thrombus. J Atheroscler Thromb 2011, 18(7):604-615. 10.5551/jat.6965, 21628951.
13. Marupudi NI, Han JE, Li KW, Renard VM, Tyler BM, Brem H. Paclitaxel: a review of adverse toxicities and novel delivery strategies. Expert Opin Drug Saf 2007, 6(5):609-621. 10.1517/14740338.6.5.609, 17877447.
14. Htay T, Liu MW. Drug-eluting stent: a review and update. Vasc Health Risk Manag 2005, 1(4):263-276. 10.2147/vhrm.2005.1.4.263, 1993957, 17315599.
15. Schwartz RS, Edelman E, Virmani R, Carter A, Granada JF, Kaluza GL, Chronos NA, Robinson KA, Waksman R, Weinberger J, Wilson GJ, Wilensky RL. Drug-eluting stents in preclinical studies: updated consensus recommendations for preclinical evaluation. Circ Cardiovasc Interv 2008, 1(2):143-153. 10.1161/CIRCINTERVENTIONS.108.789974, 2935144, 20031669.
16. Suzuki T, Kopia G, Hayashi S, Bailey LR, Llanos G, Wilensky R, Klugherz BD, Papandreou G, Narayan P, Leon MB, Yeung AC, Tio F, Tsao PS, Falotico R, Carter AJ. Stent-based delivery of sirolimus reduces neointimal formation in a porcine coronary model. Circulation 2001, 104(10):1188-1193. 10.1161/hc3601.093987, 11535578.
17. Schwartz RS, Huber KC, Murphy JG, Edwards WD, Camrud AR, Vlietstra RE, Holmes DR. Restenosis and the proportional neointimal response to coronary artery injury: results in a porcine model. J Am Coll Cardiol 1992, 19(2):267-274. 10.1016/0735-1097(92)90476-4, 1732351.
18. Golovina VA, Blaustein MP. Preparation of primary cultured mesenteric artery smooth muscle cells for fluorescent imaging and physiological studies. Nat Protoc 2006, 1(6):2681-2687.
19. Ho FM, Liu SH, Liau CS, Huang PJ, Lin-Shiau SY. High glucose-induced apoptosis in human endothelial cells is mediated by sequential activations of c-Jun NH(2)-terminal kinase and caspase-3. Circulation 2000, 101(22):2618-2624. 10.1161/01.CIR.101.22.2618, 10840014.
20. Cipolla MJ. Elevated glucose potentiates contraction of isolated rat resistance arteries and augments protein kinase C-induced intracellular calcium release. Metabolism 1999, 48(8):1015-1022. 10.1016/S0026-0495(99)90199-3, 10459567.
21. Wilson GJ, Nakazawa G, Schwartz RS, Huibregtse B, Poff B, Herbst TJ, Baim DS, Virmani R. Comparison of inflammatory response after implantation of sirolimus- and paclitaxel-eluting stents in porcine coronary arteries. Circulation 2009, 120(2):141-149. 10.1161/CIRCULATIONAHA.107.730010, 19564562.
22. Beyer-Mears A, Bucci FA, Del Val M, Cruz E. Dietary myo-inositol effect on sugar cataractogenesis. Pharmacology 1989, 39(1):59-68. 10.1159/000138572, 2587618.
23. Farb A, Heller PF, Shroff S, Cheng L, Kolodgie FD, Carter AJ, Scott DS, Froehlich J, Virmani R. Pathological analysis of local delivery of paclitaxel via a polymer-coated stent. Circulation 2001, 104(4):473-479. 10.1161/hc3001.092037, 11468212.
24. Nakazawa G, Finn AV, Vorpahl M, Ladich ER, Kolodgie FD, Virmani R. Coronary responses and differential mechanisms of late stent thrombosis attributed to first-generation sirolimus- and paclitaxel-eluting stents. J Am Coll Cardiol 2011, 57(4):390-398. 10.1016/j.jacc.2010.05.066, 21251578.
25. Finn AV, Kolodgie FD, Harnek J, Guerrero LJ, Acampado E, Tefera K, Skorija K, Weber DK, Gold HK, Virmani R. Differential response of delayed healing and persistent inflammation at sites of overlapping sirolimus- or paclitaxel-eluting stents. Circulation 2005, 112(2):270-278. 10.1161/CIRCULATIONAHA.104.508937, 15998681.
26. Wilson GJ, Polovick JE, Huibregtse BA, Poff BC. Overlapping paclitaxel-eluting stents: long-term effects in a porcine coronary artery model. Cardiovasc Res 2007, 76(2):361-372. 10.1016/j.cardiores.2007.07.004, 17716637.
27. Llano R, Winsor-Hines D, Patel DB, Seifert PS, Hamamdzic D, Wilson GJ, Wang H, Keane MG, Huibregtse BA, Wilensky RL. Vascular responses to drug-eluting and bare metal stents in diabetic/hypercholesterolemic and nonatherosclerotic porcine coronary arteries. Circ Cardiovasc Interv 2011, 4(5):438-446. 10.1161/CIRCINTERVENTIONS.110.959957, 21972400.
28. Joner M, Nakazawa G, Finn AV, Quee SC, Coleman L, Acampado E, Wilson PS, Skorija K, Cheng Q, Xu X, Gold HK, Kolodgie FD, Virmani R. Endothelial cell recovery between comparator polymer-based drug-eluting stents. J Am Coll Cardiol 2008, 52(5):333-342. 10.1016/j.jacc.2008.04.030, 18652940.
29. Sheehy A, Hsu S, Sinn I, Tai J, Kolodgie FD, Nakazawa G, Yazdani SK, Quee SC, Virmani R, Polyakov I. Vascular response to coronary artery stenting in mature and juvenile swine. Cardiovasc Revasc Med 2011, 12(6):375-384. 10.1016/j.carrev.2011.05.003, 21741885.
30. Nakazawa G, Finn AV, Ladich E, Ribichini F, Coleman L, Kolodgie FD, Virmani R. Drug-eluting stent safety: findings from preclinical studies. Expert Rev Cardiovasc Ther 2008, 6(10):1379-1391. 10.1586/14779072.6.10.1379, 19018691.
31. Nakazawa G, Nakano M, Otsuka F, Wilcox JN, Melder R, Pruitt S, Kolodgie FD, Virmani R. Evaluation of polymer-based comparator drug-eluting stents using a rabbit model of iliac artery atherosclerosis. Circ Cardiovasc Interv 2011, 4(1):38-46. 10.1161/CIRCINTERVENTIONS.110.957654, 21205943.
32. Wilson GJ, Huibregtse BA, Stejskal EA, Crary J, Starzyk RM, Dawkins KD, Barry JJ. Vascular response to a third generation everolimus-eluting stent. EuroIntervention 2010, 6(4):512-519. 10.4244/EIJ30V6I4A85, 20884440.
33. Finn AV, Kolodgie FD, Nakano M, Virmani R. The differences between neovascularization of chronic total occlusion and intraplaque angiogenesis. JACC Cardiovasc Imaging 2010, 3(8):806-810. 10.1016/j.jcmg.2010.03.011, 20705259.
34. Farb A, Weber DK, Kolodgie FD, Burke AP, Virmani R. Morphological predictors of restenosis after coronary stenting in humans. Circulation 2002, 105(25):2974-2980. 10.1161/01.CIR.0000019071.72887.BD, 12081990.
35. Grewe PH, Deneke T, Machraoui A, Barmeyer J, Muller KM. Acute and chronic tissue response to coronary stent implantation: pathologic findings in human specimen. J Am Coll Cardiol 2000, 35(1):157-163. 10.1016/S0735-1097(99)00486-6, 10636274.
36. Schomig A, Kastrati A, Wessely R. Prevention of restenosis by systemic drug therapy: back to the future?. Circulation 2005, 112(18):2759-2761. 10.1161/CIRCULATIONAHA.105.583484, 16267248.
37. Radeleff B, Lopez-Benitez R, Stampfl U, Stampfl S, Sommer C, Thierjung H, Berger I, Kauffmann G, Richter GM. Paclitaxel-induced arterial wall toxicity and inflammation: tissue uptake in various dose densities in a minipig model. J Vasc Interv Radiol 2010, 21(8):1262-1270. 10.1016/j.jvir.2010.02.020, 20656224.
38. Wu-Wong JR, Chiou WJ, Dickinson R, Opgenorth TJ. Endothelin attenuates apoptosis in human smooth muscle cells. Biochem J 1997, 328(Pt 3):733-737. 1218979, 9396713.
39. Clarke MC, Figg N, Maguire JJ, Davenport AP, Goddard M, Littlewood TD, Bennett MR. Apoptosis of vascular smooth muscle cells induces features of plaque vulnerability in atherosclerosis. Nat Med 2006, 12(9):1075-1080. 10.1038/nm1459, 16892061.
40. Heldman AW, Cheng L, Jenkins GM, Heller PF, Kim DW, Ware M, Nater C, Hruban RH, Rezai B, Abella BS, Bunge KE, Kinsella JL, Sollott SJ, Lakatta EG, Brinker JA, Hunter WL, Froehlich JP. Paclitaxel stent coating inhibits neointimal hyperplasia at 4 weeks in a porcine model of coronary restenosis. Circulation 2001, 103(18):2289-2295. 10.1161/01.CIR.103.18.2289, 11342479.
41. Lee RM, Masaki T, Yang HS, Liu J, Chen J, Li L, Blumenthal DK, Cheung AK. Different signaling responses to anti-proliferative agents in human aortic and venous smooth muscle cells. J Cell Biochem 2006, 99(3):835-844. 10.1002/jcb.20903, 16721826.
42. Zeng G, Nystrom FH, Ravichandran LV, Cong LN, Kirby M, Mostowski H, Quon MJ. Roles for insulin receptor, PI3-kinase, and Akt in insulin-signaling pathways related to production of nitric oxide in human vascular endothelial cells. Circulation 2000, 101(13):1539-1545. 10.1161/01.CIR.101.13.1539, 10747347.
43. Hasanbasic I, Cuerquis J, Varnum B, Blostein MD. Intracellular signaling pathways involved in Gas6-Axl-mediated survival of endothelial cells. Am J Physiol Heart Circ Physiol 2004, 287(3):H1207-H1213. 10.1152/ajpheart.00020.2004, 15130893.
44. Jia H, Liu H, Kong J, Hou J, Wu J, Zhang M, Tian J, Ma L, Hu S, Huang X, Zhang S, Yu B, Jang IK. A novel polymer-free paclitaxel-eluting stent with a nanoporous surface for rapid endothelialization and inhibition of intimal hyperplasia: Comparison with a polymer-based sirolimus-eluting stent and bare metal stent in a porcine model. J Biomed Mater Res A 2011, 98(4):629-637.
45. Richter Y, Edelman ER. Cardiology is flow. Circulation 2006, 113(23):2679-2682. 10.1161/CIRCULATIONAHA.106.632687, 16769924.
46. Stone GW, Midei M, Newman W, Sanz M, Hermiller JB, Williams J, Farhat N, Mahaffey KW, Cutlip DE, Fitzgerald PJ, Sood P, Su X, Lansky AJ. Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial. Jama 2008, 299(16):1903-1913. 10.1001/jama.299.16.1903, 18430909.
47. Kereiakes DJ, Cutlip DE, Applegate RJ, Wang J, Yaqub M, Sood P, Su X, Su G, Farhat N, Rizvi A, Simonton CA, Sudhir K, Stone GW. Outcomes in diabetic and nondiabetic patients treated with everolimus- or paclitaxel-eluting stents: results from the SPIRIT IV clinical trial (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System). J Am Coll Cardiol 2010, 56(25):2084-2089. 10.1016/j.jacc.2010.10.006, 21144968.